非奈利酮在射血分数轻度降低或保留的心力衰竭女性和男性中的疗效与安全性:FINEARTS-HF随机临床试验的二次分析
FINEARTS-HF试验的预设二次分析纳入6001例LVEF≥40%的症状性心衰患者(女性45.5%),比较非奈利酮与安慰剂。非奈利酮降低主要复合终点(心血管死亡和总心衰事件)的风险在女性和男性中相似(女性率比0.78,95%CI 0.65-0.95;男性0.88,95%CI 0.74-1.04;非奈利酮在女性和男性中耐受性相似。
要点
- 女性主要终点发生率略低于男性(15.7 vs 16.8/100人年)。
- 非奈利酮在女性和男性中耐受性相似。
核心结论
- 在FINEARTS-HF中,非奈利酮在女性和男性射血分数轻度降低或保留的心力衰竭患者中相似地降低主要终点风险。
- 非奈利酮在女性和男性中耐受性相似。
研究设计与样本
- 预设分析基于FINEARTS-HF三期随机临床试验,该试验在37个国家653个中心开展。
- 纳入6001例年龄≥40岁、有症状且LVEF≥40%的心衰患者,2020年9月至2023年1月随机分组。
- 干预为非奈利酮(滴定至20 mg或40 mg)或安慰剂。
主要发现
- 女性2732例(45.5%),平均(SD)年龄73.6(9.1)岁。
- 女性较男性有更高的任何肥胖率、更高的LVEF(54.6% vs 50.9%)、更低的平均eGFR(59.7 vs 64.1;P<.001)、更差的NYHA功能分级和更低的KCCQ-TSS(62.3 vs 71.0)。
- 主要终点发生率女性略低(15.7;95%CI 14.3-17.3)于男性(16.8;95%CI 15.4-18.3)/100人年。
临床怎么用
- 对于LVEF≥40%的心衰患者,非奈利酮的疗效和耐受性在女性和男性中相似,支持在不同性别中应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Sex is associated with the clinical presentation, outcomes, and response to treatment in patients with heart failure (HF). However, little is known about the safety and efficacy of treatment with finerenone according to sex. OBJECTIVE: To estimate the efficacy and safety of finerenone compared with placebo in both women and men. DESIGN, SETTING, AND PARTICIPANTS: Prespecified analyses were conducted in the phase 3 randomized clinical trial Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure (FINEARTS-HF). The trial was conducted across 653 sites in 37 countries. Participants were adults aged 40 years and older with symptomatic HF and left ventricular ejection fraction (LVEF) of 40% or greater randomized between September 2020 and January 2023. INTERVENTION: Finerenone (titrated to 20 mg or 40 mg) or placebo. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of cardiovascular death and total (first and recurrent) HF events (unplanned HF hospitalizations or urgent HF visits). RESULTS: A total of 6001 patients were randomized in FINEARTS-HF, of whom 2732 were women (45.5%), with a mean (SD) age of 73.6 (9.1) years. Women had higher rates of any obesity, higher LVEF (54.6 [7.6%] vs 50.9 [7.6] for men), lower mean (SD) estimated glomerular filtration rate than men (59.7 [19.1] vs 64.1 [20.0] for men; P<.001) , worse New York Heart Association functional class, and lower Kansas City Cardiomyopathy Questionnaire-Total Symptom Scores (KCCQ-TSS) (mean [SD] 62.3 [24.0] vs 71.0 [23.1]). The incident rate of the primary outcome was slightly lower in women (15.7; 95% CI, 14.3-17.3) than in men (16.8; 95% CI, 15.4-18.3) per 100 person-years. Compared with placebo, finerenone reduced the risk of the primary end point similarly in women and men: rate ratio 0.78 (95% CI, 0.65-0.95) in women and 0.88 (95% CI, 0.74-1.04) in men (P = .41 for interaction). Consistent effects were observed for the components of the primary outcome and all-cause mortality. The mean increase (improvement) in KCCQ-TSS from baseline to 12 months was greater with finerenone, regardless of sex (P = .73 for interaction). Finerenone had similar tolerability in women and men. CONCLUSIONS AND RELEVANCE: In FINEARTS-HF, finerenone reduced the risk of the primary end point similarly in women and men with heart failure with mildly reduced or preserved ejection fraction. Finerenone had similar tolerability in women and men. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04435626.
引用
- Chimura, Wang, Jhund, et al. Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025. PMID: 39550721. doi:10.1001/jamacardio.2024.4613
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。